Dr. Corey Cutler Elected President of ASTCT for 2024-2025
Corey Cutler, MD, MPH Named 2024-2025 President of ASTCT ● Photo Credit: American Society for Transplantation and Cellular Therapy
CHICAGO, March 11, 2024 (VSNewsNetwork.com) - The American Society for Transplantation and Cellular Therapy® (ASTCT®) has named Dr. Corey Cutler as its President for the 2024-2025 term. A longstanding member since 2002 and a previous member of the Board of Directors since 2009, Dr. Cutler brings a wealth of experience and dedication to the role.
Currently serving as the Director of the Adult Stem Cell Transplantation Program at the Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School, Dr. Cutler has been at the forefront of transplantation medicine and research.
Upon accepting the presidency, Dr. Cutler expressed his enthusiasm and vision for the future of ASTCT, stating, “I am honored to take over this role and build on the successful foundation that my predecessors have established. In my role as President of ASTCT, I will advocate for our patients and support our field by advancing science and education for our community."
Dr. Cutler's academic credentials include an MPH degree from the Harvard School of Public Health. His research has primarily focused on novel prophylaxis and therapy for acute and chronic graft-vs-host disease, as well as decision theory in stem cell transplantation. With over 300 peer-reviewed publications and numerous contributions to books and reviews, Dr. Cutler is a respected voice in the transplantation community.
The ASTCT also announced the complete list of its Board of Directors for the 2024-2025 term in a press release, featuring distinguished professionals from across the field of transplantation and cellular therapy. This leadership team is poised to guide the Society in its mission to improve patient outcomes through research, education, and advocacy.
For more information about the ASTCT and its initiatives, visit their website at www.astct.org.
Source: American Society for Transplantation and Cellular Therapy (ASTCT) via Newswire
